Pending further research, the SET, a brief, inexpensive, and nontechnical measure of speedy eye movement, may serve as a visual/oculomotor indicator of cognitive impairment in multiple sclerosis.

Both vision and cognitive problems are commonplace in multiple sclerosis. Previous research suggests that MS patients with compromised near vision perform more poorly on visually mediated cognitive tests. Consequently it has been recommended that neuropsychologists who evaluate MS patients with poor corrected near vision should rely primarily on auditory neuropsychological tests. However, no research has examined the association between vision problems and performance on non-visual neuropsychological tests in MS. Moreover, little if any research has examined the association between more sensitive measures of vision impairment and cognitive difficulties in MS. The objective of this study was to examine the relationship between visual acuity and cognition in MS. A total of 65 MS patients were administered a visual and neuropsychological evaluation. Visual examination included an assessment of visual acuity, low-contrast visual acuity (5%, 2.5%, and 1.25% illuminated charts) and near visual acuity. Poorer high-contrast, near, and low-contrast visual acuity were significantly associated with poorer performance on visual, non-visual, and motor-based neuropsychological tests. Neuropsychologists should be aware that poor corrected vision in MS is associated with poor performance in all cognitive and motor domains. Results suggest the need for further exploration of visual acuity biomarkers of disease progression in MS.

The Alzheimer’s Disease Assessment Scale (ADAS-Cog) has become the de facto gold-standard for assessing the efficacy of putative anti-dementia treatments. There has been an increasing interest in providing greater standardization, automation, and administration consistency to the scale. Recently, electronic versions of the ADAS-Cog (eADAS-Cog) have been utilized in clinical trials and demonstrated significant reductions in frequency of rater error as compared to paper. In order to establish validity of the electronic version (eADAS-Cog), 20 subjects who had received a diagnosis of probable Alzheimer’s disease (AD) at a private US Memory Clinic completed a single-center, randomized, counterbalanced, prospective trial comparing a version of the eADAS-Cog to the standard paper scale. Interclass Correlation Coefficient on total scores and Kappa analysis on domain scores yielded high agreement (0.88 – 0.99). Effects of order and mode of administration on ADAS-Cog total scores did not demonstrate a significant main effect. Overall, this study establishes adequate concurrent validity between the ADAS-Cog and eADAS-Cog among an adult population with diagnosed AD.

No abstract

No abstract